Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study

Figures & data

Table 1 The Baseline Patients’ Characteristics

Characteristics	Results (n)
Age (years)	59 (43–75)
FIGO Stage
IIIA	2
IIIB	1
IIIC	15
IV	10
Differentiation
I	1
II	5
III	22
Cytoreductive surgery
Optimal	11
Suboptimal	15
Unknown	2
Number of prior chemotherapy regimens
2	6
3	8
≥3	14
Dose reduction
Yes	4
No	24

Abbreviation: n, number of patients.

Figure 1 Patient disposition.

Abbreviations: EOC, epithelial ovarian cancer; CR, complete response; PR, partial response; PD, progressive disease.

Table 2 Treatment-Related Toxicities

Adverse Event	Grade1 n	Grade2 n	Grade3 n	Grade4 n	Total n(%)
Hand and foot syndrome	9	6			53.57
Secondary hypertension	8	3	2		46.43
Fatigue	2	2			14.29
Anorexia	1				3.57
Neutropenia	2				7.14
Thrombocytopenia			3		10.71
Diarrhea	3				10.71
Liver dysfunction	1				3.57
Nausea		1			3.57

Abbreviation: n, number of patients.

Figure 2 Kaplan-Meier estimates of PFS (A) and OS (B) of 28 patients with epithelial ovarian cancer after apatinib treatment.

Abbreviations: PFS, progression-free survival; OS, Overall survival.